Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | AGER | Q15109 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.37 |
| ▸ | EIF4E | P06730 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15033935 | 0.89 | GRM5 (0.43) | PTGS1PTGS2GABRA2GABRB2ALDH1A1 | |
| SCHEMBL15033977 | 0.88 | GABRA2 (0.47) | PTGS1PTGS2GABRA2GABRB2ALDH1A1 | |
| SCHEMBL15033978 | 0.85 | GABRA2 (0.43) | PTGS1GABRA2GABRB2AGERMAPT | |
| SCHEMBL15034001 | 0.84 | MAPT (0.51) | PTGS1GABRA2GABRB2AGERMEN1 | |
| SCHEMBL15019885 | 0.84 | GABRA2 (0.42) | PTGS1GABRA2GABRB2AGERMAPT | |
| SCHEMBL15034007 | 0.81 | ALDH1A1 (0.49) | PTGS1PTGS2ALDH1A1MEN1KMT2A | |
| SCHEMBL15046477 | 0.80 | GRM5 (0.43) | PTGS1PTGS2GABRA2GABRB2ALDH1A1 | |
| SCHEMBL15034535 | 0.80 | GRM5 (0.60) | PTGS1PTGS2ALDH1A1GRM5 | |
| SCHEMBL15034539 | 0.79 | GRM5 (0.51) | MEN1KMT2AGRM5 | |
| SCHEMBL15046474 | 0.79 | ALDH1A1 (0.45) | PTGS1PTGS2GABRA2GABRB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791117-B1 | 4-ARYL IMIDAZOLE DERIVATIVES AS MGLU5 POSITIVE ALLESTERIC MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2016-03-16 | — | — | EP | disclosed |
| US-8937176-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937176-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8716277-B2 | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-06 | — | — | US | disclosed |
| US-8716277-B2 | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-06 | — | — | US | disclosed |
| US-20130158011-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158011-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| WO-2013087807-A1 | 4-ARYL IMIDAZOLE DERIVATIVES AS MGLU5 POSITIVE ALLESTERIC MODIULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | WO | disclosed |
| US-20130158038-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158038-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158011-A1 | NOVEL COMPOUNDS | GRM5, GRM1, GRIK5 | PTGS1 1273/4885PTGS2 2193/4885GABRA2 84/4885 |
| US-20130158038-A1 | NOVEL COMPOUNDS | GRM5, GRIN1, GRM1 | PTGS1 1134/4885PTGS2 1861/4885GABRA2 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.